• Home
  • Our Pipeline
  • About Us
  • Science
    • Active Immunotherapies
    • GlyMab®
  • News
  • Investors
    • Share Info
    • Financial Info
    • Documents & Presentations
    • Corporate Governance
  • Publications
  • Contact Us
    • Find a trial
    • Become an Investigator

Edison Report – Redesigning immunity: The next frontier in immuno-oncology

by admin | Mar 4, 2026 | Circulars

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Scancell Financial Year 2026 Interim Results

by chantal | Jan 29, 2026 | Investor Presentations, Investors, Presentations

H126: solid iSCIB1+ data underpins planned progress

by alex | Jan 29, 2026 | Immunobody, iSCIB1+, Moditope, SCIB1, Trinity Delta Reports

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

FDA clears global Phase III trial for iSCIB1+

by alex | Jan 26, 2026 | Immunobody, iSCIB1+, Moditope, SCIB1, Trinity Delta Reports

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

ESMO IO: Refining Standard of Care in Advanced Melanoma

by chantal | Dec 12, 2025 | Investor Presentations

CEO Phil L’Huillier gives Report on Melanoma trial success to Proactive

by chantal | Dec 12, 2025 | Investor Presentations

« Older Entries

Recent Posts

  • Scancell Receives FDA Fast Track Designation for iSCIB1+
  • Scancell announces CFO Transition
  • Edison Report – Redesigning immunity: The next frontier in immuno-oncology
  • Scancell Financial Year 2026 Interim Results
  • H126: solid iSCIB1+ data underpins planned progress

Recent Comments

No comments to show.

Scancell is focused on developing novel immunotherapies for the treatment of cancer and was founded in 1996 based on research led by Professor Lindy Durrant at the University of Nottingham in the UK.

  • Follow
  • Follow

About Us
Leadership Team
Science
Our Pipeline
News
Contact Us
Find a Trial
Become an Investigator

ACTIVE IMMUNOTHERAPY

ImmunoBody®
Moditope®

ANTIBODIES

GlyMab®
AvidiMab®

Investors
Company Profile
Advisors
Corporate Governance
Documents & Presentations
Share Information
Financial Information

Copyright © 2026 Scancell | Website Designed & Developed by Identity Creative | Privacy & Cookie Policy